Motor Neuropathy, Sensory Neuropathy
Conditions
Keywords
Covid-19, Nerve conduction studies, Neuropathy, Complication
Brief summary
SARS-COV-2 infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. our aim is to evaluate neurological impact of covid-19; if there is any.
Detailed description
Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological and psychosocial impairments. Literature regarding the sensory and motor affection of COVID-19 is still limited. Public health emergencies as COVID-19 are likely to cause adverse neuropsychiatric impacts. Cognitive impairments after SARS-COV-2 infection were noticed, COVID-19 patients complain of poor concentration, declined memory, and insomnia, as well as anxiety and depression symptoms. in a study; Neurological manifestations described in 36.4% of 214 patients with confirmed COVID-19. However, the symptoms described \[dizziness (not further defined), headache, and impaired consciousness\] are commonplace in many severe infections and represent disturbances in neurological function rather than a neurological disease per se. Anosmia and ageusia have received much attention, but are ubiquitous in other common upper respiratory tract infections. While a reported increased risk of cerebrovascular disease.
Interventions
None listed
Sponsors
Assiut University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
20 Years to 68 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with confirmed RT-PCR COVID-19 infection with mild to moderate severity based on the Egyptian ministry of health (MOH) protocol (version 1.4, November 2020) with neurological symptoms suggestive of peripheral neuropathy
Exclusion criteria
* patients presenting with neurological manifestations other than peripheral neuropathy, such as stroke, cerebral hemorrhage, encephalitis, or meningitis. * Patients with any medical condition or comorbidities that may affect the result of the study as diabetes, arthritis, and carpel tunnel syndrome. * Severe COVID-19 patients with a critical condition that needs hospitalization and ventilatory support were also excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Motor nerve function | 1 MONTH | The motor nerve study was performed in the median and posterior tibial nerve to assess the motor function of the upper and lower limbs; included Compound motor action potential (CMAP), Motor nerve conduction velocity (MNCV), and nerve conduction latency recording. |
| Sensory nerve function | 1 MONTH | The sensory nerve study was done for the median and sural nerves including Sensory motor nerve conduction amplitude, latency, and velocity were recorded. |
Countries
Egypt
Outcome results
None listed